Podcasts about DME

We discuss long term results of faricimab treatment of DME, with the first author of the Ophthalmology article on the results of Rhone-X trial, Dr. Veeral Sheth, Director of Clinical Research at University Retina in Chicago.

Gaining global consensus on DME needs will dictate the terms of future drug development. Can the findings from the DME AWARE Delphi study help? Baruch Kuppermann, MD, PhD, joins the show to review the findings from a 25-doctor panel of global experts. What did they conclude regarding the unmet needs in DME?

In this episode of the Industry Matters podcast, Tyler Coulander sits down with Alan Morris to explore what makes the VGM Heartland Conference a must-attend event for the HME and DME industry. As Heartland celebrates its 25th anniversary, Tyler and Alan break down why this year's conference is more relevant than ever — from navigating margin pressure and evolving payer networks to leveraging technology for operational efficiency. Whether you're a business owner, an operator, or an emerging leader, they share why Heartland delivers practical, actionable takeaways you won't find anywhere else. If you're serious about growing your business and staying ahead of the industry's biggest challenges and opportunities, this episode — and this conference — is for you.Watch on YouTube: https://youtu.be/zW2UrWjREAs

With an abundance of therapeutic options for managing diabetic macular edema (DME), what patient characteristics inform your treatment decisions? Does the number of loading doses influence long-term macular fluid outcomes? How are you managing insurance-mandated step-therapy in your patients? In today's episode, host Dr. Jay Sridhar invites Drs. Durga Borkar and Carl Danzig to share how they've integrated new anti-VEGF therapies into clinical practice. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Quita Highsmith is the VP of population health at Genentech, but more importantly, she's a friend of The MM+M Podcast. In her third appearance on the show, she discusses Genentech's All Eyes on DME campaign featuring comedian Damon Wayans. Launched this spring, All Eyes on DME is the drugmaker's pop culture-focused way to talk about a condition in diabetic macular edema that is both often overlooked and disproportionately impacts patients of color.  Additionally, Highsmith reflects on her decades working in healthcare and why the work doesn't stop for her or Genentech.  And for our Trends segment, we're talking with our editor-at-large Steve Madden about his time in Las Vegas covering the Enhanced Games and what it means for medical marketers. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

What does it look like when healthcare finance, strategy, and vision all collide in one extraordinary facility?Device Nation is privileged to bring you the story of Indiana Orthopedic Institute's CFO, Jennifer Fry, CPA!From a childhood shaped by veterinary medicine to the C-suite of one of America's most impressive ambulatory surgery centers, Jennifer's path through healthcare is anything but ordinary.She's held the room at Franciscan Alliance, St. Vincent Health, Athens Medical Group, and J&J Fry Consulting. She's navigated acquisitions, joint ventures, physician practice management, and interim strategy roles at a major not-for-profit health system.Now, as CFO of the newly built Indiana Orthopedic Institute in Noblesville, Indiana, she's helping lead what we believe will be a blueprint for the future of specialty ASC care.In this episode:

In this episode of The Retina Channel Podcast, Dr. Jennifer Sun joins Dr. Keyvan Koushan to discuss the Phase 2 results of DRCR Retina Network Protocol AN evaluating tonabersat for diabetic macular edema. Dr. Sun reviews the rationale behind targeting connexin-43–mediated inflammatory pathways in DME, the key efficacy and safety findings from the study, and the potential implications of this novel oral therapy for future diabetic retinal disease management. The conversation also explores broader trends in DRCR clinical research and emerging treatment paradigms in diabetic eye disease.

Welcome to a special episode of HME News in 10, sponsored by Rhythm Healthcare.  In this episode, Mitch Yoel, chief operating officer at Rhythm Healthcare, shares what it really takes for durable medical equipment (DME) providers to rise to the top of a hospital's referral list.  His starting point is simple but critical:  Does your messaging sound transactional, or does it sound clinical and compelling?  “I believe the future winners – especially in oxygen therapy – won't just be equipment distributors,” he said. “They'll be clinically fluent partners, helping hospitals improve outcomes after discharge.”  Yoel breaks down what it takes to become that partner, from leveraging evidence-based decisions to eliminating disconnects around equipment selection.  Hosts:  Liz Beaulieu  Theresa Flaherty   Guest:  Mitch Yoel 

In this episode of IM: Unfiltered, Lindy Tentinger (President, VGM & Associates) and Ike Isaacson (SVP of Government & Regulatory Relations, VGM Group) sit down with Joel Gallion, CEO of Bellevue Healthcare in Washington, for a candid conversation about the urgency of advocacy in the home health and DME industry.They unpack the real risks behind new payer and TPA models reshaping care delivery — from sole sourcing and network restrictions to the erosion of quality and competition — drawing a stark parallel to what the PBM model did to independent pharmacies.Joel shares how Bellevue Healthcare went from advocacy bystanders to active champions of change through their state association PAMES, and why he believes the time to act is now, not tomorrow. Whether you're a large supplier or a small independent provider, this episode is a call to step up, get involved, and own your role in shaping the future of the industry.Watch on YouTube: https://youtu.be/6TTJ4e7ch5g

From Snowboarding Trip to Nationwide Sleep Business | Bretton Lane on Building Patient-First Sleep CareHow does a snowboarding trip turn into building a nationwide sleep business?In this episode of SleepTech Talk, we sit down with Bretton Beine Lane, President of BetterNight, to unpack her unconventional journey from the slopes to scaling one of the country's leading sleep care organizations.With more than a decade of experience in sleep medicine leadership and operations, Bretton has helped transform sleep care delivery—focusing on improving patient outcomes at scale through innovation and operational excellence.But her story isn't just about business growth—it's about mindset.

Diabetes doesn't just affect blood sugar—it can quietly and progressively steal vision. In this episode of The Aging Well Podcast, Dr. Jeff Armstrong is joined by Dr. Matthew Cunningham, a retina specialist, to unpack diabetic macular edema (DME), one of the most common and underdiagnosed causes of vision loss among adults with diabetes.We explore how DME develops, why it often goes unnoticed until damage is already done, and what patients—and practitioners—can do to intervene earlier. The conversation also addresses a critical and often overlooked issue: the disproportionate burden of diabetic eye disease in the Black community and other underserved populations.Using the “All Eyes on DME” campaign as a springboard, this episode bridges clinical insight with real-world application—equipping listeners with the knowledge to protect their vision, advocate for better care, and age well with clarity and purpose.Learn more at https://www.alleyesondme.com/Please, support The Aging Well Podcast by hitting the ‘like' button, subscribing/following the podcast, sharing with a friend, and….Tip Jar! All donations support this podcast to keep it going. https://paypal.me/theagingwellpodcastBUY the products you need to… age well from our trusted affiliates and support the mission of The Aging Well Podcast*.The Aging Well Podcast merchandise | Show how you are aging well | Use the promo code AGING WELL for free shipping on orders over $75 | https://theagingwellpodcast-shop.fourthwall.com/promo/AGINGWELLAuro Wellness | Glutaryl—Antioxidant spray that delivers high doses of glutathione (“Master Antioxidant”) and the new Copper Tripeptide (GHK-Cu) | 10% off Code: AGINGWELL at https://aurowellness.com/agingwellpodcastNutritional Biochemical Inc. (NBI) | Trusted supplement. NBI stands 100% behind the quality of their formulations and the science on which they're based. | Click the following link and use the discount code AGINGWELL for 10% off: https://shop.nbihealth.com/agingwellJigsaw Health | Trusted supplements. “It's fun to feel good.” | Click the following link and use the discount code AGINGWELL for 10% off: https://bit.ly/4ks3Y0OBerkeley Life | Optimize nitric oxide levels | Purchase your starter kit at a 15% discount | Use the promo code: AGINGWELL15 | https://berkeleylife.pxf.io/c/6475525/3226696/31118Oxford Healthspan | Primeadine®, a plant-derived spermidine supplement | 10% off code: AGINGWELL | https://www.oxfordhealthspan.com/AGINGWELLKneeMo | A smart device programmed to reduce your knee pain and keep you moving. | Click the following link and use the discount code AGINGWELL15 for 15% off: https://thekneemo.com/ref/agingwellProlon | The Fasting Mimicking Diet (FMD) is a revolutionary five-day nutrition program scientifically formulated to mimic the effects of a prolonged water fast while still allowing nourishment - supporting the benefits of fasting without the challenges and risks that come from water-only fasts. | For the best available discount always use this link: https://prolonlife.com/theagingwellpodcastThrive25 | Your personal longevity advisor | https://www.thrive25.com/early-access?via=william-jeffreyFusionary Formulas | Combining Ayurvedic wisdom with Western science for optimal health support. | 15% off Code: AGINGWELL | https://fusionaryformulas.com?sca_ref=9678325.IHg5xYhdOzzke8ZrDr Lewis Nutrition | Fight neurodegeneration and cognitive decline with Daily Brain Care by Dr Lewis Nutrition—a proven daily formula designed to protect and restore brain function. | 10% off code: AGINGWELL or use the link: https://drlewisnutrition.com/AGINGWELL*We receive commission on these purchases. Thank you.

Improve real-world DME outcomes by mastering the interpretation of evolving biomarkers and the latest evidence on long-acting anti-VEGF therapies. Credit available for this activity expires: [04/28/27] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/diabetic-macular-edema-express-q-whats-new-2026a1000czk?ecd=bdc_podcast_libsyn_mscpedu

La parentalité végane est-elle un danger pour la santé des enfants ou un levier pour une société plus juste ? Dans ce nouvel extrait de "Quelques minutes avec...", nous levons le voile sur un sujet qui cristallise autant de peurs que de préjugés.Pour ce teaser exclusif, Cédric Rostein échange avec Emilie Leblanc (fondatrice de "Petits mais Veggie") et Astrid Prévost (nutritionniste-diététicienne). Ensemble, elles déconstruisent les idées reçues sur l'alimentation végétale des enfants, de la naissance à 12 ans. ✨ Ce que vous allez découvrir dans cet extrait :Le véganisme au-delà de l'assiette : Pourquoi ce choix est avant tout une démarche éthique globale qui refuse l'exploitation animale sous toutes ses formes (habillement, loisirs, etc.). Le grand mythe des protéines : Pourquoi la peur des carences est souvent injustifiée et quelle est la réalité des besoins nutritionnels des enfants. Le défi de l'école et de la cantine : Pourquoi le repas végan est, contre toute attente, le plus inclusif et laïque qui soit. L'empathie naturelle de l'enfant : Comment nos enfants perçoivent spontanément les animaux comme des amis à protéger plutôt que comme de la nourriture.

Chronic conditions like obesity, diabetes, COPD, and congestive heart failure are reshaping the U.S. healthcare system — and the demand for durable medical equipment along with it. In this episode of Industry Matters, VGM's Tyler Coulander and Alan Morris dig into the data behind America's growing chronic disease burden, what it means for DME providers navigating the shift from hospital-based to home-based care, and why demand for equipment and long-term patient support is more resilient than ever. They also tackle the big GLP-1 question: do drugs like Ozempic threaten CPAP and diabetes equipment markets, or do they actually open new doors? Tune in for a high-level look at the forces driving industry growth — and check out the VGM Industry Insights library for a deeper dive into the data.Watch the video version on YouTube: https://youtu.be/rwZAg90E3d8

Proposer un morceau de brocoli ou de banane à un bébé de 6 mois ? Pour beaucoup, c'est l'angoisse assurée.Bienvenue dans Le Focus, le format court de Papatriarcat. Aujourd'hui, on s'attaque à la peur numéro 1 de l'alimentation autonome : la peur des morceaux et de l'étouffement.Loin des idées reçues, on t'explique la mécanique incroyable du corps humain.Dans cet épisode, tu découvriras :La différence vitale entre le "réflexe nauséeux" (impressionnant mais sécuritaire) et le véritable étouffement (silencieux).Pourquoi les études prouvent que la DME n'est pas plus dangereuse que les purées.Les 5 règles strictes et non-négociables pour donner des morceaux en toute sécurité (tomates cerises entières = danger absolu).Le conseil ultime pour faire redescendre le stress à table.Références : Cet épisode s'appuie sur le consensus pédiatrique actuel et les résultats de l'étude clinique BLISS sur la sécurité de la Diversification Menée par l'Enfant.Soutenir Papatriarcat : Si ce format t'aide à te rassurer, pense à laisser 5 étoiles ⭐⭐⭐⭐⭐ sur ta plateforme d'écoute, c'est le meilleur moyen de soutenir l'émission !Salutations adelphes et solidaires ✊

In this episode of SleepTech Talk, we sit down with Dr. Muhammad Usama, MD, FACP, DiplABOM, a triple board-certified physician in sleep medicine and obesity medicine, to explore one of the most important shifts in healthcare today.As GLP-1 medications continue to transform the obesity landscape, what does that mean for patients with sleep apnea?Dr. Usama breaks down the clinical connection between obesity and sleep-disordered breathing, and how treating one condition can significantly impact the other.

This episode recorded live at the Becker's 16th Annual Meeting features Ann Cornelius, Chief Revenue Officer, DASCO Home Medical Equipment. Here, she explores how DME joint ventures can reduce post acute leakage, improve care transitions from hospital to home, and support value based outcomes while enhancing patient experience and operational efficiency.This episode is sponsored by DASCO Home Medical Equipment,

Are patients with DR at higher risk for TDR, DME, vitreous hemorrhage, or blindness based on race or ethnicity ? Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, about a large retrospective cohort study examining more than 627,000 US patients with DR. The panel examines why Black and Hispanic patients faced significantly higher rates of adverse outcomes at  1 and 5 years after diagnosis and unpacks what confounding variables the study could not capture. They consider what these findings should mean for screening strategies, patient education, and the day-to-day management of high-risk diabetic patients in clinic.

New Episode Alert!What happens when sleep health meets social media influence?In this episode of SleepTech Talk, we sit down with Lindsay McFarland—better known as @yoursleepbff—to explore how she built a powerful platform educating thousands about sleep apnea, with a special focus on women.Sleep apnea is often underdiagnosed in women, and Lindsay is working to change that narrative—one post at a time.We dive into:How Lindsay became a rising voice in sleep health on social mediaWhy women are often overlooked in sleep apnea diagnosis and treatmentThe most common questions she gets from her audienceHow education and awareness can drive better outcomes and adherenceThe role of social platforms in reshaping patient engagementWhether you're a sleep clinician, DME provider, or someone struggling with PAP adherence, this episode highlights the growing importance of meeting patients where they are—online.

Please visit answersincme.com/AGN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses anti-VEGF treatment of diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti–vascular endothelial growth factor (VEGF) therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Vous sentez parfois la pression de bien faire à l'heure des repas avec vos enfants? Dans cet épisode, on jase sans filtre avec Cosette Gergès, nutritionniste et cofondatrice de Nutritionnistes en pédiatrie, autrice des livres Les petits mangeurs intuitifs. Ensemble, on explore :   La fameuse “pression de performance” autour de l'alimentation Le casse-tête de l'introduction des aliments (DME, purées… que choisir?) Comment gérer les repas où vos enfants n'ont qu'une envie : danser plutôt que manger! Les attentes réalistes selon l'âge et le tempérament Le partage des responsabilités à table : qui fait quoi? Nos fameux commentaires et le rôle du ketchup (oui, on en parle!) Les lunchs boudés, le gaspillage, la flexibilité et la culpabilité parentale Des pistes concrètes pour retrouver le plaisir de manger en famille   Avec beaucoup de bienveillance (et une bonne dose de gros bon sens!), on se donne la permission d'être des parents parfaitement imparfaits. Venez découvrir comment nourrir une belle relation avec la nourriture… et avec nos cocos! Bonne écoute — et sentez-vous libres de partager vos impressions en écrivant un commentaire ou de laissez 5 étoiles! Ça aide vraiment à faire connaître le balado !   Pour recevoir votre dose hebdomadaire de réconfort directement dans votre boîte courriel, c'est ici!    Ce balado est présenté par Info Justice. Info Justice offre  du soutien juridique gratuit et confidentiel pour accompagner les personnes dans leurs réalités juridiques, partout au Québec. Pour en savoir plus, cliquez juste ici : https://bit.ly/infojustice-maman

Tyler Coulander sits down with Alan to break down the biggest themes and takeaways from Medtrade 2026 in Arizona. From the resurgence of competitive bidding and federal anti-fraud initiatives to AI innovation reshaping the DME ecosystem, they explore what these developments mean for providers and the industry at large. They also discuss the record-setting attendance growth, the surge in demand for education sessions, and the advocacy efforts underway to protect suppliers of all sizes. Whether you're a seasoned industry veteran or new to the HME space, this episode offers a forward-looking view of where the DME industry is headed in 2030 and beyond.View the video version on YouTube: https://youtu.be/U2dBjnT0x_0

Join Alec Hogg for today's edition of BizNews Daybreak to cut through the noise and get the essential global and local business news you need to start your week. In this episode, we cover: Global Tensions & Oil Shocks: US President Trump issues a strict ultimatum to Iran regarding the Strait of Hormuz, sparking significant volatility in the oil market. Consequently, South Africans must brace for brutal fuel price hikes, with DME now calculating that the current under-recovery is R8.80 per litre for petrol and a massive R15.10 per litre for diesel. Totalitarian Transformation? Sakeliga CEO Piet le Roux delivers a scathing critique of South Africa's BBBEE policies, arguing that the transformation framework is fundamentally totalitarian. SA as a 'Mafia State': In the wake of rising organised crime and targeted assassinations, Jonathan Deal speaks out on the political manipulation of the SAPS and the grim reality that South Africa is increasingly operating as a mafia state. Energy & Climate Narratives: At BNC#8 Nick Hudson took aim at the all-encompassing push for renewable energy in South Africa, characterising the climate crisis narrative as a "scam" orchestrated by global financial establishments. Market Wrap: A quick look at the overnight markets, featuring a drop in gold prices and stagnant movement for Bitcoin.

Loss of mobility can happen gradually or suddenly, making everyday activities more challenging for older adults and the families who support them. In this podcast, join host Karen Summey, MA, ACAPcommunity Project Manager and Podcast Host, Active Family Caregiver and Mr. Bill Price, Owner, Mobility Scooters and More, Roswell, GA as they explore how to recognize when it may be time to consider mobility solutions and how to assess changing physical needs and limitations. Learn about common types of durable medical equipment (DME)—such as canes, walkers, wheelchairs, and other assistive devices—and how to select options that promote safety, independence, and quality of life. Experts share practical guidance to help caregivers and their families make informed decisions with confidence.  Click here to view the slides from this episode! For information on additional podcasts, FREE in-person programs for care partners (caregivers), and more, please visit the ACAPcommunity website here.   No chapter in your area? Stay tuned! ACAP is growing nationwide. Check our website often for a chapter near you. Meanwhile, we hope you'll take advantage of our audio podcast archive, our YouTube archive, and more.   This episode of The Caregiver Community is made possible by our podcast sponsor, Senior TLC in Newton, NC, and sustaining partner EveryAge.

DME-11 - HR with IEDs

ENTER NOW  Win 3 Months of FREE Leads (Bracket Giveaway)The Lead Heroes Bracket Giveaway is LIVE — and this is your chance to turn your picks into real leads.https://site.leadheroes.com/march-madness-2026?fbclid=IwY2xjawQnzqhleHRuA2FlbQIxMABicmlkETFDYTlESXN0OGhhcExnajE0c3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHrdy6MkamkEymu5XwtMrJ0E7utg_z77lGvIKOD4eFSXA3XKoGiAic_A4698b_aem_wofuRypLcyFjVWJD6uBs1QJoin us at Seven Figure Blueprint Live and take your Medicare business to the next level: https://live.sevenfigure.com In this episode of the Seven Figures or Bust Podcast, the hosts break down the shocking CMS freeze on DME providers and what it signals for the future of healthcare and insurance. They dive into the rise of fraudulent operations, recent investigations exposing fake clinics, and how these crackdowns are impacting legitimate businesses and agents. The conversation uncovers the deeper issues within the system, the risks to Medicare integrity, and what insurance professionals need to watch out for as regulations tighten and enforcement ramps up. 

DME 38 — Ultra Music Festival and Miami Music Week 2026 Pre-game. All the best new tunes that will be played across Miami from 21-28 March. We start in the tech house genre, building into melodic techno and finishing with trance. Features Mau P, Joris Voorn, Camelphat, Anyma and more. #DME #MelodicTechno #MiamiMusicWeek #Ultra20026 #TechHouse1. How's Your Evening So Far (Chris Lake Extended) - Josh Wink & Lil' Louis, Chris Lake2. Neck (Extended Mix) - Mau P3. Discoteka (Extended Mix) - Benny Benassi, Tobias Gerard4. Inferno (Original Mix) - Max Styler5. Caramelle (Extended Mix) - Mesto6. Galvanize (Chris Lake Extended Mix) - The Chemical Brothers7. Alive (Remix) (Alok Extended Remix) - Empire Of The Sun8. You & Me (Extended Mix) - Max Styler9. Born Slippy (Extended Mix) - Deadline, KVSH, GOLDZBROUGH10. Get'Da (Original Mix) - Landau, Eemoz11. Lick (Extended Mix) - SIDEPIECE12. Party All The Time (Adam Beyer, Layton Giordani & Green Velvet Remix) (Adam Beyer Layton Giordani & - Sharam13. Expanse (Extended Mix) - GENESI (ITA)14. Tryptamine (Extended Mix) - Joris Voorn15. Greece 2000 (Remix) (Max Styler Extended Rework) - Three Drives, Max Styler16. Entrance (Extended Mix) - Kevin de Vries, Add-usABOUT DEEP MELODIC EUPHORIC (DME)Every month I create a compilation mix of the best new melodic house, techno, progressive, and trance from Miami, USAFollow me @DJHNNRS on Soundcloud & Instagram.Visit www.HNNRS.com for videos, gigs, and bookings.Subscribe on Apple Podcasts, Google Podcasts, Amazon Music, iHeartRadio, Pandora, Overcast, Castro, Pocket Casts, Deezer, Player FM & more.

On Episode 824 of The Core Report, financial journalist Govindraj Ethiraj talks to Dr. Ashish Lele, Director at CSIR-National Chemical Laboratory as well as Amit Kumar Sharma, Head – Americas at VFS Global.SHOW NOTES(00:00) Stories of the day(01:00) The Iran war reaches a fresh turning point as the US attempts to drag other countries into the mix falters.(03:50) Markets snap a three day run, rise on value buying.(05:49) Indian refineries are running at full steam and gas supplies are inching up, says the Government.(07:45) Can India's domestic answer to LPG, the DME, make up for shortages?(21:27) A view from visa services provider VFS on how travel has been impacted by the warRegister for our event “Who Builds the Future of AI?”https://luma.com/x6oyyjiz For more of our coverage check out ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠thecore.in⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe to our Newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow us on:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠

Join Tyler Mahncke from VGM & Associates as he sits down with Gene Richtsmeier and Michael Berling from Huntington National Bank to discuss strategic financing solutions for DME businesses. In this episode, they explore critical topics including access to capital, business expansion strategies, mergers and acquisitions, succession planning, and SBA lending options. Whether you're looking to grow your DME business, navigate an acquisition, or plan for retirement, this conversation offers practical insights on building banking relationships, understanding cash flow versus revenue, and preparing your business for long-term success. Perfect for DME providers, HME companies, and healthcare business owners seeking financial guidance in today's evolving market.Watch the video version of this podcast on YouTube: https://youtu.be/RrzbuqZuNLA

Episode 502 features Stacey's conversation with Brian Machut (Alliant Health) on how widespread Medicare fee-for-service fraud is inflating costs and undermining ACO shared savings in MSSP and ACO REACH. ACOs uncovered major urinary catheter fraud in 2023 tied to codes A4352/A4353, totaling about $3.5B, with some beneficiaries billed for items never received (including a case shared by Dr. Tara Lagu).  CMS created a "SAHS" (significant, anomalous, highly suspect) process to remove certain suspect costs, but benchmark effects can unevenly impact ACOs; catheter fraud is still projected at $3–$3.5B in 2025. The episode also highlights rapidly growing "skin substitute" spending projected at $13–$15B in 2025; CMS did not classify 2024 skin substitute costs as SAHS, leaving them in ACO performance calculations.  Machut explains this fraud and missed CMS trend projections can reduce provider earnings, discourage participation in value-based care, and potentially drive cost shifting into higher commercial rates—affecting plan sponsors such as self-insured employers. === LINKS ===

Drs. Vakharia and Danzig highlight new AAO 2025 data on high-dose aflibercept, sleep apnea as a potential AMD risk factor, and an AI-guided anti-VEGF regimen that cuts injections while maintaining vision. Together, these advances point toward more personalized, efficient care for patients with neovascular AMD and DME.

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/Who-Needs-a-TKI-Identifying-the-Right-Candidates/54101/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/So-You-Think-You-Want-a-TKI/54102/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/To-Implant-or-to-Inject/54100/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery systems. Detailed overviews of clinical programs (eg, LUGANO, LUCIA, SOL-1, SOL-R) highlight ongoing phase 3 studies evaluating efficacy and treatment intervals. Real-world case discussions further illustrate patient types who may benefit from these investigational agents. The conversation concludes with considerations for integrating TKIs into future practice. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.75.

Jeff & Shannon dissect Hillary Clinton's Epstein deposition chaos, Haiti ties, surging elite resignations, and Trump's massive healthcare fraud crackdown live. Tune in at Rumble, YouTube, X and Red State Talk Radio now! Patriots, strap in—@intheMatrixxx and @shadygrooove, the unyielding truth-seekers, tear into Season 8, Episode 038, “Hillary Clinton Deposed in Epstein Investigation; Track Resignations,” as Hillary Clinton's closed-door House Oversight deposition in Chappaqua unfolds today with her opening statement denying any knowledge of Epstein's crimes or ever meeting him, only for the session to pause amid a leaked unflattering photo allegedly from Rep. Lauren Boebert, exposing establishment denials and contradictions tied to documented Clinton Foundation emails coordinating Haiti relief through Epstein-linked jets and the Laura Silsby child trafficking intervention scandal. They spotlight the accelerating wave of high-profile resignations linked to Epstein revelations, including World Economic Forum CEO Børge Brende stepping down after scrutiny of his dinners and communications with Epstein, alongside exits from figures like Rothschild Bank leadership, Nobel winners, and more, signaling mounting elite accountability. Layered in: JD Vance and Dr. Mehmet Oz unveiling the Trump admin's aggressive CRUSH fraud initiative, deferring $259.5 million in Minnesota Medicaid funds over fake autism diagnoses and deceased beneficiary billings, imposing a national DME moratorium to halt $1.1 billion in orthotic brace scams, and crowdsourcing public tips to slash billions in waste—proving real action protects taxpayers and vulnerable Americans. With live reactions to Clinton's testimony, Haiti proxy past connections, and fraud distractions masking deeper trafficking issues, the duo delivers raw, no-holds-barred analysis rejecting mainstream spin. The truth is learned, never told; the constitution is your weapon—tune in at noon-0-five Eastern LIVE to stand with Trump! MG Show: America First MAGA Podcast & Conservative Talk Show Launched in 2019 and now in Season 8, the MG Show is your go-to source for unfiltered truth on Trump policies, border security, economic nationalism, and exposing globalist psyops. Hosted by Jeffrey Pedersen (@InTheMatrixxx) and Shannon Townsend (@ShadyGrooove), it champions sovereignty, traditional values, and critiques of establishment politics. Tune in weekdays at 12pm ET / 9am PT for patriotic insights strengthening the Republic under President Trump's America First agenda. Hosts - Jeffrey Pedersen (@InTheMatrixxx): Expert in political analysis and exposing hidden agendas, with a focus on Trump's diplomatic wins and media bias. - Shannon Townsend (@ShadyGrooove): Delivers sharp insights on intelligence operations, Constitutional rights, and defenses of Trump's strategies against mainstream critiques. Where to Watch & Listen Catch live episodes or on-demand replays packed with MAGA victories like inflation drops, border awards, Trump pardons, and psyop exposures: - Live Streams: https://rumble.com/mgshow for premium America First content. - Radio: https://mgshow.link/redstate on Red State Talk Radio. - X Live: https://x.com/inthematrixxx for real-time pro-Trump discussions. - Podcasts: Search "MG Show" on PodBean, Apple Podcasts, Pandora, and Amazon Music. - YouTube: Full episodes at https://youtube.com/c/inthematrixxx and https://www.youtube.com/c/TruthForFreedom. Follow for daily pro-Trump alerts: - X: @InTheMatrixxx (https://x.com/inthematrixxx) and @ShadyGrooove (https://x.com/shadygrooove). Support the MG Show Fuel the MAGA movement against establishment lies: - Donate: https://mg.show/support or contribute at https://givesendgo.com/helpmgshow. - Merch: https://merch.mg.show for official gear. - MyPillow Special: Use code MGSHOW at https://mypillow.com/mgshow. - Crypto: https://mgshow.link/rumblewallet. All Links Everything MG Show Related: https://linktr.ee/mgshow. MG Show Anthem Get chills with the patriotic track: https://youtu.be/SyfI8_fnCAs

Join host Boone Lockard, VP of HME, Respiratory, & Wellness at VGM, as he sits down with Matt Stephenson, R&D Manager at Fisher & Paykel Healthcare, to explore the newly launched Nova Nasal mask. With nearly 20 years of experience designing respiratory therapy products, Matt shares the patient-centered research and innovative engineering behind this next-generation nasal mask. Discover the key features that set Nova Nasal apart: the intuitive SwingFit headgear system for easy fitting, RollFit cushion technology that adapts to different nose shapes, and advanced diffuser technology for quieter, more comfortable sleep. Matt discusses how the design team focused on stability, comfort, and ease of use while reducing the mask's footprint by 10% to minimize claustrophobia and improve the user experience. Whether you're a respiratory therapist, DME provider, or sleep therapy professional, this episode offers valuable insights into the latest advancements in OSA therapy and what makes a truly patient-focused mask design.

In this episode, Candice sits down with Dr. Shivani Gupta, Ayurvedic practitioner, turmeric researcher, and author of The Inflammation Code. Dr. Shivani shares her personal health journey from being chronically sick as a child to discovering the healing power of Ayurveda in India. That turning point led her to dedicate her life to helping women reduce inflammation, balance hormones, improve gut health, and reclaim their energy naturally.   In this episode, they discuss: How Dr. Shivani's early health struggles shaped her path to Ayurvedic medicine The connection between chronic inflammation, brain fog, joint pain, weight gain, and fatigue Why turmeric and curcumin play a powerful role in reducing systemic inflammation How modern lifestyle factors increase inflammation in the body The critical role of sleep in clearing inflammation and restoring health What Elemental Design means and how understanding your body type can transform your wellness journey Why women's health is entering a new era of awareness and empowerment   This conversation is a powerful reminder that the body is designed to heal, and when ancient wisdom meets modern science, true vitality becomes possible.   About Dr. Shivani Gupta: Dr. Shivani Gupta is an Ayurvedic practitioner, turmeric researcher, and speaker who blends classical Ayurveda with functional medicine to help women calm inflammation, balance hormones, and restore energy. With a Master's in Ayurvedic Sciences and a PhD focused on turmeric, she translates ancient wisdom into simple daily rituals—Elemental Design™ personalization, Mental Inflammation™ resets, gut/estrobolome support, and spice-based micro-habits. Her book, The Inflammation Code (Hay House, February 2026), available now, is a practical, non-diet system for cooling chronic inflammation to improve brain fog, bloat, pain, sleep, and mood. Dr. Shivani is the host of the Fusionary Health Podcast and creator/host of the Emmy-nominated TV show Vibrant Health with Dr. Shivani Gupta, syndicated across the Southeast with a DME reach of ~6 million. A sought-after educator for midlife hormone health and metabolism, her work has been featured in MindBodyGreen, wellness summits, and regional TV and radio. She's spent over 20 years helping women and families build sustainable routines that actually stick—in real life. Learn more at shivanigupta.com.   Website: www.shivanigupta.com Use code "passion" to receive 15% off your Fusionary Formula Purchase The Inflammation Code book: www.theinflammationcode.com 7-Day Inflammation Detox Challenge:https://www.7dayinflammationdetox.com/optin1641313075014 Anti-Inflammatory E-Cookbook:https://drive.google.com/file/d/1ItNJ1DV3XsOn5MwBbSpeTFH8o3KFu2qk/view?usp=sharing Instagram: @dr.shivaniguptahttps://instagram.com/dr.shivanigupta/ Facebook: @theshivaniguptahttps://www.facebook.com/theshivanigupta YouTube: @dr.shivaniguptahttps://www.youtube.com/@dr.shivanigupta Pinterest: @theshivaniguptahttps://www.pinterest.com/theshivanigupta ----- Connect with Candice Snyder! Website: https://www.podpage.com/passion-purpose-and-possibilities-1/ Facebook: https://www.facebook.com/candicebsnyder?_rdr Passion, Purpose, and Possibilities Community Group: https://www.facebook.com/groups/passionpurposeandpossibilitiescommunity/ Instagram: https://www.instagram.com/passionpurposepossibilities/ LinkedIn: https://www.linkedin.com/in/candicesnyder/ Shop For A Cause With Gifts That Give Back to Nonprofits: https://thekindnesscause.com/ Fall In Love With Artists And Experience Joy And Calm: https://www.youtube.com/@movenartrelaxation

In this episode, host Erin Gallardo, PT, DPT, NCS interviews the Motus Nova clinical team—occupational therapists Jamie Kurtz, MS, OTR/L, Keisha Burrous, OTR/L, CBIS, Amie Canning, MS, OTR/L, and Mirasol Jacobs, PT, DPT — about the Motus Hand and Motus Foot robotic devices for neurorehabilitation. The team explains how these FDA Class I medical devices provide active-assistive, game-based training at home to help patients achieve the high repetition doses (500–600 reps per day) needed for neuroplastic change, without replacing traditional therapy. Built on pneumatic "artificial muscle" technology, the devices adapt in real time to the user's movement, address tone and spasticity, and can be customized for a wide range of neurologic conditions, from stroke and MS to Parkinson's disease and Guillain-Barré. The conversation covers who is appropriate for the devices, how they integrate with inpatient and outpatient care, real-world success stories—including improved gait, grip strength, and mental health—and the practical steps for clinicians to refer patients, arrange demos, and navigate the 13‑month rental-to-own DME model now supported by a dedicated Medicare code, which means patients can get the device through their insurance and it does not impact their ability to get other durable medical equipment (DME). Overall, the episode highlights Motus Nova as an accessible way to extend evidence-based neuro rehab beyond the clinic and into patients' homes. You will likely have a patient (or several) who come to mind while listening to this, so check it out and learn more today! Keisha Burrous LinkedIN Motus Nova https://motusnova.com Therapists! Contact Motus Nova with questions, schedule an inservice, or refer a patient here: clinical@motusnova.com

Dr. Shivani Gupta is an Ayurvedic practitioner, turmeric researcher, and speaker who blends classical Ayurveda with functional medicine to help women calm inflammation, balance hormones, and restore energy. With a Master's in Ayurvedic Sciences and a PhD focused on turmeric, she translates ancient wisdom into simple daily rituals—Elemental Design™ personalization, Mental Inflammation™ resets, gut/estrobolome support, and spice-based micro-habits. Her forthcoming book, The Inflammation Code (Hay House, February 2026), is a practical, non-diet system for cooling chronic inflammation to improve brain fog, bloat, pain, sleep, and mood. Dr. Shivani is the host of the Fusionary Health Podcast and creator/host of the Emmy-nominated TV show Vibrant Health with Dr. Shivani Gupta, syndicated across the Southeast with a DME reach of ~6 million. A sought-after educator for midlife hormone health and metabolism, her work has been featured in MindBodyGreen, wellness summits, and regional TV and radio. She's spent over 20 years helping women and families build sustainable routines that actually stick—in real life. Learn more at shivanigupta.com. Website: www.shivanigupta.com The Inflammation Code book: www.theinflammationcode.com  Fusionary Formulas: www.fusionaryformulas.com 7-Day Inflammation Detox Challenge: https://www.7dayinflammationdetox.com/optin1641313075014 Anti-Inflammatory E-Cookbook: https://drive.google.com/file/d/1ItNJ1DV3XsOn5MwBbSpeTFH8o3KFu2qk/view?usp=sharing     15% OFF use THINKFITNESSLIFE   Only buy what you need, use Think Fitness Life's trusted affiliates when the service/supplement is right for you.  For Physical Assistance Think Fitness Life Coaching is backed by 25 years of Experience guiding people to fitness freedom. Learn more Mention "Kickstart discount" for 10% off your first month.   For Therapy Services we partnered with BetterHelp: A telehealth therapy service connecting people with licensed mental health therapists. Learn more By using the referral link you receive 10% off your first month. Disclaimer: We're here to share ideas and inspiration, not medical advice. Please check with your doctor before making any changes to your health or fitness routine  

Please visit answersincme.com/YMM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nitish Mehta, MD; and Sarwar Zahid, MD. In this activity, experts in diabetic retinopathy discuss long-acting anti-VEGF agents and strategies to improve outcomes for patients with diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti-VEGF therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Think ownership requires slow growth? Think again. Independent pharmacy owner Kyle Beyer joins us to discuss how he went from chain pharmacist to multi-location owner of North Shore Pharmacy in only five years. He talks about the opportunities and obstacles of ownership: from buying during COVID, building a compounding hub, scaling through partner networks, and navigating the changing landscape of PBMs. If you're wondering what it really takes to grow in today's industry, Kyle's is the success story you need to hear. 00:00 – Welcome & Guest Introduction 01:30 – The North Shore Expansion Story (3 Locations & Growing) 07:54 – Buying a Pharmacy Right Before COVID Hit 11:14 – Building a Compounding Hub & New Revenue Streams 13:19 – Partner Network Success & the Rise of the “Sticky Patient” 17:26 – Supplements, DME & Front-End Profit Strategies 23:29 – Scaling With Technology: Processes, Staff & Pioneer Features 33:15 – Medicare True-Ups & What Pharmacy Owners Should Watch  Hosted By: Johnathon Duhon | VP of PMS Sales, RedSail Technologies Guest: Kyle Beyer | Owner, North Shore Pharmacy  Looking for more information about independent pharmacy? Visit https://www.redsailtechnologies.com 

Join Tyler Coulander and Alan Morris as they break down the key takeaways from the 2026 JP Morgan Healthcare Conference and explore what these industry trends mean for the DME sector. In this episode, they discuss five critical themes shaping the future of healthcare: health systems stabilization and how hospitals are getting back to basics with cost control and operational efficiency, AI's evolution from buzzword to proven ROI in documentation and clinical operations, the resurgence of M&A activity and why strategic partnerships are becoming increasingly important, the impact of GLP-1 medications on diabetes management and sleep apnea treatment, and navigating payer and policy dynamics including Medicare Advantage changes and the One Big Beautiful Bill. Whether you're looking to strengthen health system relationships, invest in AI strategically, or prepare for industry consolidation, this episode provides actionable insights to help DME providers stay ahead of the curve in 2026 and beyond.

In this episode of 1st Talk Compliance, Kevin Chmura is joined by Robyn Johns, as they discuss recent updates to their November live webinar, Compliance Cliffs: Navigating Telehealth Waivers and Reimbursement Changes. Learn how the policy landscape has shifted in recent months—especially around telehealth flexibilities, controlled substance prescribing, and the 2026 CMS payment rules.   Kevin Chmura Welcome to 1st Talk Compliance. I’m Kevin Chmura, CEO of Panacea Healthcare Solutions. Today we’re bringing you a timely update on our November live webinar, Compliance Cliffs: Navigating Telehealth Waivers and Reimbursement Changes. Since that webinar, several policy changes have moved quickly, especially in telehealth flexibilities. Controlled substance prescribing and 2026 CMS payment rules. Before we jump in, just a quick note. 1st Talk Compliance is brought to you by 1st Healthcare Compliance, a part of Panacea Healthcare Solutions. We help healthcare organizations strengthen their compliance programs with practical education tools and compliance management support. So teams can reduce risk, keep pace with regulatory change and operate with confidence. Now I’m pleased to welcome back Robyn Johns from Med USA. Robyn, thanks for coming back. Robyn Johns Thanks, Kevin. I’m happy to be here. Kevin Chmura  Great. So, let’s jump in. So, in November on the webinar, we spent a lot of time on what people were calling the telehealth cliff, which was creating a tremendous amount of uncertainty on whether flexibilities would expire. Can you catch us up on what the status is now? Robyn Johns  Yeah. The major update is that the spending package released on January 20th includes extensions of the telehealth flexibilities all the way through December 31st of 2027. Kevin Chmura So that’s a pretty meaningful runway. That’s great, but I guess doesn’t eliminate compliance obligations, but it is reducing near-term uncertainty which give everybody some time to standardize workflows. So, it’s in the news, but maybe you could tell. So, what’s in the spending package at a high level and what should healthcare leaders like us be paying attention to? Robyn Johns   Right. So, it was the one from the 20th was a $1.2 trillion spending package released by the House Appropriations Committee and it was just passed yesterday on the 22nd in two separate votes by the full House. So, those bills included the remaining six of the twelve appropriations necessary to avert a government shutdown. So that’s good news for everyone. If we can get them across the finish line, they funded many of the federal government agencies such as HHS, Labor, Defense, HUD, and also Homeland Security. That was a contentious one. That’s why they had to do two separate votes. It funds them through fiscal year 2026, which ends on September 30th of this year. Kevin Chmura  So, OK, so we have a funding package with multiple healthcare policy riders. Not, I guess not too surprising in today’s day and age. So, besides the telehealth through 2027, what else is included in there that compliance and operational leaders should know about? Robyn Johns   So the writers also include PBM reform and it extends hospital at home actually through 2030, which is another one that hit a lot of facilities hard with the government shutdown. It extends Medicare dependent hospital and low volume hospital programs, which is really beneficial for our rural providers and it delays the Medicaid disproportionate share cut again until fiscal year 2028. Notably, for a lot of people, it does not include an extension of the ACA subsidies, which were such a sticking point in the government shutdown last fall. Kevin Chmura  Yeah, that that that last point is operationally really important and coverage instability often turns into eligibility churn and puts real pair mix pressures on the you know same patients, different coverage, right.? And that’s just you know probably increases downstream compliance and documentation stress. Yeah that’s a that’s a tough one. So what’s the timing of congressional action now? Robyn Johns So with the House passing all of the bills, they now send the full appropriations package to the Senate. The Senate will take all of that up when they return from recess on Monday the 26th, and will hopefully pass them all ahead of the January 30th deadline. And hopefully without any significant changes which might require them to go back to the house because the house will be on recess next week. Kevin Chmura  Wow. So split schedule, it’s why we should keep ourselves in a monitoring posture. I guess we should always be monitoring, but things are moving pretty quickly right now and you sort of get into that world of what is expected is not what’s in effect. Which is always, always a tough place to operate, but hey, that’s healthcare, isn’t it? So, given the extension to 2027, in your opinion, what should compliance teams be doing now? Like what’s some practical next steps? Robyn Johns First, you’ll want to make sure that your internal policies and educational materials reflect what’s currently in effect. No major changes since most of those telehealth things were extended, but it’s always good to double check because lots of things change around the beginning of the year. Also validate your payer specific rules. Medicare policy direction is influential, but commercial payers and state laws differ. So, you got to make sure that you are matching up with those differences. And then third, we should we talk about strengthening your auditing of documentation, the modifiers, your place of service, medical necessity, all of those things that can vary depending on the payer and the specific situation of the patient. Kevin Chmura  Yeah, that that payer variation point is where a lot of organizations end up being exposed, I guess, right? Telehealth’s not really governed by one rule. You’ve got federal policy, state overlays, and then you have commercial policy updates really coming at you a number of different ways. So, I guess a good controls to maintain maybe a payer policy matrix and try to align it into your documentation and coding guidance. Probably a solid piece of advice. Robyn Johns   Absolutely. Kevin Chmura   Yeah. So, let’s move on to probably one of the highest risk areas that we covered in the webinar, and that’s controlled substance prescribing via telehealth. What’s the latest there? Robyn Johns   Good news there as well. At the end of the year, DEA and HHS extended the telehealth flexibilities for prescribing controlled substances through this year, December 31st of 2026. There are a few rules that can apply, but because they extended the flexibilities, it’s pretty much status quo until they change it again at the end of the year. Kevin Chmura   Cool, so that’s a critical compliance area because of the high risk profile and it that really includes some regulatory scrutiny and enforcement, not really just a reimbursement issue. Robyn Johns   Yes, it’s highly watched. Kevin Chmura   Yeah. And I guess as well, it should be. So given that, what control should organizations prioritize right now to reduce risk in that area? Robyn Johns  Definitely you’ll want to have clear prescribing policies, good documentation standards, and role-based training. Also, usually they want to include identity verification and required checks when they’re applicable, and consistent auditing to ensure that your process is followed, not just written down. This is another area where state regulations can vary, so you would want to make sure that you are compliant in every state where you see patients. Kevin Chmura   Yes and you’re the expert, not me. But I guess I’d add if you expand health to if you expand the telehealth quickly, take time now to ensure your governance is mature. And I’m thinking credentialing, supervision, documentation and audit trails always the basics that can help you pulled up under scrutiny. Robyn Johns   Definitely. When you expand quickly, sometimes you sacrifice certain things for speed. So, you have a minute now to go back now that you’re sure that those policies aren’t changing anytime soon to just go back and make sure that everything’s in place, all of those areas. Kevin Chmura  Yeah, I mean like any business runs better and with certainty, but at healthcare we rarely have that. So, great. So, moving on to the 2026 CMS updates that that we talked about a little bit. So, there’s been some changes in payment policy that are driving operational changes and it’s where those operational changes come in, where we introduce compliance risks if teams can’t keep pace and often they can’t. So, what are the 2026 physician fee schedule highlights? Robyn Johns   Yeah. So, we talked about these back in November and of course they went into place at the beginning of this year. So, a little bit of good news there with the conversion factor. It included the 2.5% increase that had been mandated by Congress. It also included a .75% increase for clinicians in advanced APMs or a .25% increase for clinicians who participate in MIPS or who are exempt. And then there was also a .49 budget neutrality increase. Kevin Chmura So, so the real impact varies by payer mix, site of service and quality of participation. What about RVU related changes? Robyn Johns   So that’s kind of the devil in the details there. It also implemented a -2.5% efficiency adjustment on certain non-time based services to the physician work RVU and there is also a + or -50% practice expense RVU adjustment for facility based services. So, it’s -50% if it’s facility based services or a +50% for non-facility based services. Kevin Chmura   Wow. So site of service is increasingly strategic and it’s where we see compliance issues often arise, right? You get inconsistent documentation, coding and policy adoptions across different departments and locations. Certainly not easy. Robyn Johns   No. Something you definitely need to watch closely because it is different depending on where you are and what services you’re providing. Kevin Chmura   Yeah. So, one other hotspot or another hotspot that that we often see is incident to. What's going on there? Robyn Johns  So the physician fee schedule in that they updated the definition of direct supervision for incident to billing to permanently allow supervision through real-time audio video communication except for services that have a 10 or a 90-day global surgery period. So, the supervising physician no longer has to be physically present in the office suite, they just have to be immediately available through real time audio video communication. Kevin Chmura   OK, so that’s operationally pretty significant, right? But I guess the compliance take away is relatively simple. If you’re using remote supervision, your incident to workflows must be precise. I guess who supervises, how it’s documented, and where the exceptions apply as precise as you can make all of those, huh? Robyn Johns   Yes, absolutely. Because you are relying on remote supervision, you’ll want to make sure that that is documented very effectively. Kevin Chmura   Yeah, cool. So, what about the OPPS and ASC final rule highlights for 2026? Robyn Johns Yeah. For those that these apply to, there was a 2.6% increase as well in the payment rates. They also expanded hospital price transparency requirements and we’re seeing a lot more attention and probably enforcement in that as well. There was a three-year phase out of the inpatient only list. Site neutral payments were expanded to include Drug Administration Services and the ASC covered procedures list is expanded much in relation to the inpatient only list Phase out. Kevin Chmura Yeah, that that that that’s an interesting one. So the phase out of the inpatient only list is a real operational shift and it’s one of those opportunities for providers to move volume to better cost locations, but really your compliance needs to follow those patients, right and where you’re having them. And so, when your volume moves, audits and education have to move with it, which is probably a challenge and what we know and we at our parent company, at Panacea, price transparency just remains a compliance and reputational priority because failures lead to penalties, but bad data also leads to a lot of scrutiny. So, good that there’s some, you know some guidance there, but it’s clear that those are going to be things that really need to be paid attention to from a compliance perspective. Robyn Johns Yes, for sure. Kevin Chmura So it was hard to watch the news over the last, I don’t know, six to twelve months without talking about the One Big Beautiful Bill Act. So, we’ve been tracking it. I know you’ve been tracking it. So, what’s the timing on practice impacts that you expect? Robyn Johns So most of those One Big Beautiful Bill Act Medicaid requirements that are likely to impact practices, they don’t actually begin until January of 2027. So, practices still have some time to continue their assessment and preparation for those. The immigrant eligibility changes do take effect on October 1st of this year, 2026. So that’s a little bit shorter period of time, but you do have a little bit of time to continue to figure out how that may affect your practice if you have a high number of Medicaid patients, and prepare for the ways that you can offset those eligibility changes and payment requirements. Kevin Chmura Yeah, that clarity on the effective dates really can help teams allocate resources correctly and that’s often a challenge especially when you’re tracking proposed rules versus final rules and not sure when things will go into effect. So that’s good. So, as you’re looking out on the landscape in 2026, what are some of your top compliance priorities that you’re advising organizations to focus on? Robyn Johns Yeah, we’re currently focused on probably five or so top priorities for 2026, not in any specific order, but we are watching data privacy and security. Part of that is because HIPAA updates are underway to both the privacy and security rules, though timelines are unclear. We’re not sure when or i f we’ll see any final rules on those, but we do know that healthcare remains a prime target of cyber-attacks, so we have to constantly be vigilant to that and related to that, but also separately, is AI and other emerging technologies. AI is changing the landscape for the types of attacks we receive, but also the way we have to respond to them. It also is changing the landscape of healthcare generally, both in the provider office and at the payers and at the government. Those other emerging technologies like digital tools, those can increase the compliance risk in your environment, and we need to remember that both government and commercial payers are using AI to identify outlier claims faster and increase their auditing. Then we also have the fraud, waste and abuse enforcement. CMS we know has currently been focused a lot on Medicare Advantage, but that scrutiny can shift oversight over to providers as well because that’s where so much of the data that the Medicare Advantage plans use comes from. The OID also continues to focus on telehealth. There are other focuses are drug device and biologics and program integrity areas such as DME, Hospice and Drug Administration. So, want to make sure that you’re watching all of those if you practice there. Fourth one we have is vendor and third-party oversight. Many of the largest breaches that have we’ve seen have originated with third parties. So, organizations really need to make sure that you have careful oversight and maintain good monitoring on your third-party vendors and others who may have access to your systems and data. And finally, we know we’re going to continue to see those rapid regulatory updates. Federal and state changes often conflict. We have lots of states that are currently in their legislative period. So that will bring out some changes. And then in addition to that, commercial payers are tightening their policies and auditing in response to the pressures that are being put on that on them, whether from the government or just from a financial perspective. Kevin Chmura Yeah, it is something the pace of acceleration of some of the advances in technology and how they how they’re going to impact us. But I guess you know that’s really the reality of 2026 and beyond. You’re going to see an uptick in in in speed to policy changes, faster detection, which will be something and probably more third-party exposure as we rely on more and more vendors and others to help us do what we need to do every day, but I’m sure you know the advice I’ve heard you give many times and we have to agree with it. A strong compliance program has to be built to adapt. That means clear governance, repeatable monitoring and targeted auditing tied to the current risk with an eye on the future and where everything’s going. Robyn Johns Yeah, definitely. It’s an exciting time, lots of opportunities for improving our programs and really tightening things up to make sure that we’re protecting ourselves and all the information that we are responsible for. Kevin Chmura Yeah, great. So, Robyn, thank you for the update and for helping our listeners translate policy movement into practical compliance actions. To everyone listening, if you want the full context and deeper discussion, you can access the webinar on demand at 1st Healthcare Compliance’s website. It’s called Compliance Cliffs: Navigating Telehealth Waivers and Reimbursement Changes. Thank you for listening to 1st Talk Compliance and we’ll see you next time. Thanks, Robyn. Robyn Johns Thanks, Kevin.

Have you ever wondered why inflammation sticks around no matter how "clean" you eat or how many therapies you try? Ayurvedic practitioner and turmeric researcher, Dr. Shivani Gupta, shares her six-pillar Elemental Design, the everyday super spices you can use like medicine, and the small daily rituals that cool inflammation and restore energy—without restrictive dieting. Pre-order "The Inflammation Code" today and claim bonuses that guide you through anti-inflammatory living using super spices, lifestyle modifications, and mind-body practices: https://www.theinflammationcode.com/ In this episode, you'll learn: ⏰00:00 - Why chronic inflammation is so hard to turn off ⏰03:06 - Shivani's personal health journey and discovering Ayurveda ⏰04:58 - Hidden toxins, EMFs, and circadian rhythm challenges ⏰08:24 - The six pillars of elemental design ⏰11:40 - Mental inflammation and why it blocks healing ⏰12:34 - What is Ayurveda? ⏰15:17 - The three elemental constitutions (Vata, Pitta, Kapha) ⏰26:19 - Ayurvedic super spices and how to use them ⏰38:22 - The ONE thing you can do to activate self-healing Check out Dr. Shivani Gupta's Bio: Dr. Shivani Gupta is an Ayurvedic practitioner, turmeric researcher, and speaker who blends classical Ayurveda with functional medicine to help women calm inflammation, balance hormones, and restore energy. With a Master's in Ayurvedic Sciences and a PhD focused on turmeric, she translates ancient wisdom into simple daily rituals—Elemental Design™ personalization, Mental Inflammation™ resets, gut/estrobolome support, and spice-based micro-habits. Her forthcoming book, The Inflammation Code (Hay House, February 2026), is a practical, non-diet system for cooling chronic inflammation to improve brain fog, bloat, pain, sleep, and mood. Dr. Shivani is the host of the Fusionary Health Podcast and creator/host of the Emmy-nominated TV show Vibrant Health with Dr. Shivani Gupta, syndicated across the Southeast with a DME reach of ~6 million. A sought-after educator for midlife hormone health and metabolism, her work has been featured in MindBodyGreen, wellness summits, and regional TV and radio. She's spent over 20 years helping women and families build sustainable routines that actually stick—in real life. Learn more at shivanigupta.com. 7-Day Inflammation Detox Challenge: https://www.7dayinflammationdetox.com/optin1641313075014 Anti-Inflammatory E-Cookbook: https://drive.google.com/file/d/1ItNJ1DV3XsOn5MwBbSpeTFH8o3KFu2qk/view?usp=sharing   Connect with Dr. Shivani Gupta: Website: http://www.fusionaryformulas.com Facebook: https://www.facebook.com/theshivanigupta (@theshivanigupta) Instagram: https://instagram.com/dr.shivanigupta/ (@dr.shivanigupta) YouTube: https://www.youtube.com/@dr.shivanigupta (@dr.shivanigupta) Pinterest: https://www.pinterest.com/theshivanigupta (@theshivanigupta) ***** Hi there! I am Jane Hogan, the Wellness Engineer, and the host of Wellness By Design. I spent 30 years designing foundations for buildings until the pain and inflammation of rheumatoid arthritis led me to hang up my hard hat and follow my heart. Now I blend my backgrounds in science and spirituality to teach people how to tap into the power of their mind, body and soul. I help them release pain naturally so they can become the best version of themselves. Wellness By Design is a show dedicated to helping people achieve wellness not by reacting to the world around them but by intentionally designing a life based on what their own body needs. In this show we explore practices, methods and science that contribute to releasing pain and inflammation naturally. Learn more at https://thewellnessengineer.com Would you like to learn how to release pain by creating more peace and calm?  Download my free guided meditation audio bundle here: https://www.thewellnessengineer.com/audio-bundle    Connect with Jane:  Facebook: https://www.facebook.com/JaneHoganHealth/ Instagram: https://www.instagram.com/thewellnessengineer/

In this episode of the Medical Sales Podcast, host Samuel Adeyinka talks with Shawn Mertes about the DME and acute care side of medical device sales and why it is one of the most underrated entry points into the industry. Shawn shares his journey from respiratory therapist to territory manager, clinical specialist, and now regional sales manager at a smaller distributor, explaining how rental based equipment supports hospitals and post acute care, what differentiates distributors from large manufacturers, and why service and education often matter more than brand names. They dive into day to day life in the role, relationship driven selling, compensation expectations, leadership lessons, and what hiring managers really look for in entry level candidates who want to break into medical sales. Connect with Shawn Mertes: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

Join Tyler Coulander, Market Strategy Manager at VGM & Associates, and Alan Morris, Senior Vice President of Strategy, as they unpack the financial pressures hospitals face in 2025–2026 and highlight how DME providers can become valuable strategic partners. They break down insights from the Kaufman Hall National Hospital Flash Report, covering rising labor and drug costs, growing uncompensated care, and lingering supply chain challenges. Despite margin stabilization, hospitals still face constraints that affect throughput, length of stay, and readmissions. Tyler and Alan explain why these pressures create major opportunities for DME providers—especially during the crucial transition from hospital to home—where timely, reliable equipment delivery can reduce readmissions, support efficient discharges, and help manage variable costs. Whether you work with discharge planners or want to strengthen health system partnerships, this episode delivers clear insights into what matters most to hospital referral partners.

In this episode of SleepTech Talk, we sit down with leaders from React Health to discuss how CPAPs and masks are evolving to improve comfort, safety, and long-term patient success.Joining us are:Colleen Lance, MD, Chief Medical Officer, React HealthBill Shoop, Chief Executive Officer, React HealthWe explore React Health's newest CPAP devices — including foam-free designs and some of the quietest machines on the market — along with the latest innovations in CPAP mask technology.Rather than focusing on machines alone, React Health is building complete patient treatment ecosystems designed to improve comfort, adherence, and outcomes for people living with obstructive sleep apnea (OSA).⭐ Topics covered in this episode:How to choose the right CPAP and mask for patientsReact Health's newest foam-free, ultra-quiet CPAP devicesAdvances in CPAP mask comfort and usabilityWhy sleep therapy is shifting toward full treatment ecosystemsUpcoming technologies focused on patient comfort and adherenceThis episode is ideal for sleep clinicians, DME professionals, and patients who want a clearer understanding of where sleep therapy technology is headed.ABOUT SLEEPTECH TALKSleepTech Talk brings together leaders in sleep medicine, technology, and innovation to explore the tools and trends shaping the future of sleep health.Catch the show on most podcast platforms or on YouTubewww.youtube.com/@sleeptechtalk A huge thanks to our sponsors:React Health  https://www.reacthealth.com/Fisher & Paykel Healthcare  Discover how F&P full-face masks have led millions of people to a great night's sleep at https://www.fphcare.com/curiosityhttps://www.fphcare.com/us/homecare/sleep-apnea/More resources for clinicians can be found at Sleep Review Magazine  https://sleepreviewmag.com/Don't forget to Like, Share, and Comment! Subscribe to SleepTech Talk for more insights into sleep apnea, CPAP therapy, and innovations shaping the future of sleep care.Whether you're a sleep professional or a healthcare innovator, this episode explores the intersection of technology, patient care, and sleep medicine.Learn more about the show at https://www.sleeptechtalk.com/thetechroomCredits:Audio/ Video: Diego R Mannikarote; Music: Pierce G MannikaroteHosts: J. Emerson Kerr, Robert Miller, Gerald George MannikaroteCopyright: ⓒ 2025 SleepTech Talk ProductionsEpisode 115The views and opinions expressed by guests on SleepTech Talk are their own and do not necessarily reflect those of the podcast hosts or SleepTech Talk as a whole. This podcast is intended for educational and informational purposes only and should not be considered medical advice. Listeners are encouraged to consult with a qualified healthcare professional for any medical concerns or questions.Sleep apnea, obstructive sleep apnea, oral sleep appliance, inspire, surgery, sleep surgery, CPAP, AI, Artificial Intelligence

In this episode of the Fit Father Project Podcast, Episode 268, Dr. Anthony Balduzzi welcomes Ayurvedic expert Dr. Shivani Gupta for a powerful conversation on chronic inflammation, longevity, and how ancient Eastern medicine offers practical solutions for modern men. Dr. Shivani shares her personal journey bridging Western science with Ayurveda and explains why inflammation is the silent driver behind joint pain, metabolic decline, gut dysfunction, and burnout.You'll learn why turmeric is far more than a trendy spice, how men can use ghee and healthy fats to support gut lining and recovery, and why understanding your personal constitution (vata, pitta, kapha) is key to long-term strength and performance. This episode also explores how stress, training intensity, diet, and circadian rhythm either fuel or calm inflammation over time.If you're a man over 40 looking to stay strong, pain-free, mentally sharp, and energized for decades to come, this episode delivers practical, grounded wisdom you can start using immediately.Key TakeawaysInflammation drives joint pain, fatigue, and agingTurmeric works best at therapeutic potencyGhee supports gut lining and recoveryMen often overheat their “fire” (pitta imbalance)Constitution determines ideal diet and trainingDaily rhythms reduce long-term inflammationAncient wisdom + modern science = longevityMore About Dr. Shivani Gupta, The Inflammation Code, and Fusionary FormulasThe Inflammation Code book: www.theinflammationcode.comWebsites: drshivani.comfusionaryformulas.com/Use code FITFAMILY at checkout for 15% off Ayurvedic supplements and teas.Podcast: Fusionary Health https://podcasts.apple.com/us/podcast/fusionary-health/id1680587836Instagram: https://instagram.com/dr.shivanigupta/Facebook: https://www.facebook.com/theshivaniguptaYouTube: https://www.youtube.com/@dr.shivaniguptaPinterest: https://www.pinterest.com/theshivanigupta Biographical Information on Dr. Shivani GuptaDr. Shivani Gupta is an Ayurvedic practitioner, turmeric researcher, and speaker who blends classical Ayurveda with functional medicine to help women calm inflammation, balance hormones, and restore energy. With a Master's in Ayurvedic Sciences and a PhD focused on turmeric, she translates ancient wisdom into simple daily rituals—Elemental Design™ personalization, Mental Inflammation™ resets, gut/estrobolome support, and spice-based micro-habits.Her forthcoming book, The Inflammation Code (Hay House, February 2026), is a practical, non-diet system for cooling chronic inflammation to improve brain fog, bloat, pain, sleep, and mood. Dr. Shivani is the host of the Fusionary Health Podcast and creator/host of the Emmy-nominated TV show Vibrant Health with Dr. Shivani Gupta, syndicated across the Southeast with a DME reach of ~6 million. A sought-after educator for midlife hormone health and metabolism, her work has been featured in MindBodyGreen, wellness summits, and regional TV and radio. She's spent over 20 years...

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big FDA recall around Freestyle Libre (see more below to find out if you're affected), Dexcom launches their 15.5 day sensor, Omnipod announces enhancements, Tandem tests a fully closed loop (with high fat, high carb meals) and lots more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. Our top story this week: XX Certain glucose monitors from Abbott Diabetes Care are providing users with incorrect glucose readings, an error that has been linked with the deaths of at least seven people and more than 700 serious injuries worldwide, according to an alert from the US Food and Drug Administration.   Incorrect glucose readings can lead to improper treatment. Abbott warned that about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are affected, but no other Libre products. Patients can visit FreeStyleCheck.com to see if their sensors are affected and to get a replacement for free.   The FDA has also published specific information about the affected products in its alert. The agency considers this to be a "potentially high-risk issue" and will continue to update its website as information becomes available.   "Patients should verify if their sensors are impacted and immediately discontinue use and dispose of the affected sensor(s)," the FDA said.   https://www.cnn.com/2025/12/02/health/abbott-diabetes-glucose-monitors https://www.freestylecheck.com/us-en/home.html XX Omnipod 5 is getting some enhancements.. and Omnipod 6 is announced. The FDA cleared updates including  a lower, 100 mg/dL target glucose option and what they call a more seamless automated experience. "This is the most significant algorithm advancement to our Omnipod 5 System since its launch in 2022," said Eric Benjamin, Insulet EVP and COO. Insulet said the new 100 mg/dL target glucose expands Omnipod 5's customization range. It now features six settings between 100 mg/dL and 150 mg/dL in 10 mg/dL increments. The company said this flexibility allows healthcare providers to tailor insulin delivery more precisely. It supports individuals seeking tighter glucose management or aiming to meet specific glucose goals. Omnipod 5's latest upgrades also help users stay in "Automated Mode" with fewer interruptions, even during prolonged high glucose events. Insulet plans to launch the updates to the algorithm in the first half of 2026. The company announced plans for an Omnipod 6 – without a lot of detail - at the company's Investor Day event in November. They also talked about a new, fully closed-loop pump for the type 2 diabetes population. https://www.drugdeliverybusiness.com/insulet-fda-clearance-omnipod-5-algorithm-enhancements/ XX Dexcom, the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System will launch in the United States on Dec. 1, making it the longest-lasting CGM system with 15.5 days of wear.   Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers on Dec. 1 with full retail launch in the coming weeks. Dexcom G7 15 Day will also be covered for Medicare beneficiaries.   Dexcom G7 15 Day's industry-leading wear-time will provide fewer sensor changes, less disruption and more time for people with diabetes to benefit from life-changing CGM technology.   New with Dexcom G7 15 Day:  Longest lasting CGM system with 15.5 days of wear. Best-in-class accuracy1 with an overall MARD of 8.0%. Easier glucose management with fewer monthly sensor changes and reduced monthly waste. This follows yesterday's announcement – the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults 18 and older with Type 2 diabetes using long-acting insulin. Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as directed by their healthcare provider. At launch, Dexcom G7 15 Day will connect with the iLet Bionic Pancreas and Omnipod® 5§§. We are working closely with Tandem and look forward to extending the launch to their customers shortly as they finalize integration. For specific information on pump compatibility and availability with the Dexcom G7 15 Day system, visit Dexcom.com/connectedpumps https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Continuous-Glucose-Monitoring-System-to-Launch-on-Dec--1-in-the-United-States/default.aspx   XX A small study of ten adults with type 1 diabetes tested Tandem's new fully closed-loop "Freedom" insulin system — and the participants put it through a real-world stress test. For 72 hours in a hotel setting, they ate heavy carb-and-fat meals, skipped all meal announcements, and didn't give any mealtime insulin boluses. The system handled almost everything automatically. Researchers said the device stayed in closed-loop mode 97% of the time and there were no incidents of diabetic ketoacidosis or severe hypoglycemia reported. While using the Freedom system, participants spent a median 61% of the day in the glucose target range — slightly higher than the 56% achieved with their usual pump at home. But the biggest improvement came overnight: time in range jumped to 96% with the closed-loop system compared to just under 70% during their home-pump week. With almost zero time spent below 70 mg/dL, researchers concluded that the fully automated Tandem system was both safe and effective even with unannounced, high-impact meals — hinting at a future of diabetes management that demands less effort from users.   XX Novo Nordisk reported promising mid-stage results for its experimental drug amycretin (AM-ee-creht-in) in diabetes patients on Tuesday. Amycretin, targets both GLP-1 and amylin hormones. In this study, it helped patients with type 2 diabetes lose up to 14.5% of their body weight over 36 weeks with weekly injections, far outperforming a placebo. The oral version delivered weight loss of up to 10.1%. Rival Eli Lilly  is surging ahead with its own amylin-based drug, eloralintide, which is advancing to late-stage testing after helping patients shed as much as 20% of their weight in a mid-stage trial. https://www.cnbc.com/2025/11/25/novos-next-gen-obesity-drug-shows-positive-results-heads-to-late-stage-testing.html XX The U.S. Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those medications compared with recent annual spending, or about $8.5 billion in net covered prescription costs. The prices go into effect in 2027, including a monthly price of $274 for Novo Nordisk's popular GLP-1 drug semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes. medicare's recent net price for Ozempic, opens new tab was $428 a month, according to an analysis published in the Journal of Managed Care and Specialty Pharmacy. Medicare put the drug's list price, before confidential rebates and discounts, at $959 a month. Based on such nondiscounted list prices, Medicare said savings on the 15 drugs ranged from 38% to 85%. The annual price negotiations were established under President Joe Biden's signature Inflation Reduction Act (IRA) of 2022. Previously, Medicare was barred by law from negotiating with drugmakers. https://www.reuters.com/business/healthcare-pharmaceuticals/us-negotiated-medicare-prices-15-more-drugs-test-cost-savings-promise-2025-11-25/   XX LifeScan announced its Chapter 11 bankruptcy reorganization plan received U.S. Bankruptcy Court approval. LifeScan said it's positioned to emerge from its financial restructuring process by the end of the year. The CEO says, "This balance sheet restructuring provides a stronger foundation for LifeScan to support our base business, advance new growth strategies, and commence our journey to become one of the most comprehensive players in the glucose management space." https://www.drugdeliverybusiness.com/glucose-monitor-lifescan-emerge-from-bankruptcy/ XX An artificial intelligence (AI)-led Diabetes Prevention Program (DPP) was as effective as a traditional human-led program in achieving recommended goals for weight loss, A1c reduction, and physical activity, according to a randomized trial of adults with prediabetes and overweight or obesity. One example of a push notification: "Looks like you're at the grocery store, Rita! Want a quick list of high-fiber snacks or smart swaps to stay on track this week?" The app also provided location- and goal-based education, with gamification elements to promote engagement. Approximately one third of participants in both the AI and human-led groups achieved the primary outcome (31.7% and 31.9%, respectively). Results were consistent across sensitivity analyses and individual components of the composite endpoint. "As more AI-based programs emerge, head-to-head comparisons among different AI-DPPs will be informative. An AI-led approach will not suit everyone; some individuals benefit more from human interaction and accountability," said Mathioudakis, adding that future research should focus on best matching patients to the modalities they prefer. https://www.medscape.com/viewarticle/ai-directed-diabetes-prevention-program-effective-human-2025a1000xam XX A new study suggets metformin could help people with type 1, reducing the need for insulin.  The researchers were surprised to find that metformin did not improve insulin resistance or change blood sugar levels. This suggests that, unlike in type 2 diabetes, metformin doesn't combat insulin resistance in type 1 diabetes.   However, metformin did reduce the amount of insulin people needed to keep their blood sugar levels stable.   https://www.the-express.com/news/health/192157/diabetes-medicine-insulin-type-1 XX Beyond Type 1 launches #TheBeyondType campaign in India to combat type 1 diabetes stigma. Nick Jonas is one of the founders of Beyond Type 1, his wife, Priyanka Chopra Jonas is his partner in this new non profit. The initiative highlights inspiring individuals living with T1D and partners with local organisations to improve awareness, medical support, and community networks for affected families across the nation. India has more young people living with T1D than any other nation, yet understanding of the condition remains limited. Beyond Type 1 is partnering with grassroots organisations across high-need regions. These include HRIDAY in Delhi–NCR, Nityaasha Foundation in Pune, Gram Jyoti in Jharkhand, and SAMATVAM Trust in Bangalore—each group focusing on improving awareness, providing medical support and building stronger community networks for young people with T1D.